The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.
Elizabeth Poplin
Research Funding - Clovis
Harpreet Wasan
Honoraria - Clovis; Lilly
Lindsey Rolfe
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Mitch Raponi
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Tone Ikdahl
No relevant relationships to disclose
Ihor Bondarenko
No relevant relationships to disclose
Irina Davidenko
No relevant relationships to disclose
Volodymyr Bondar
No relevant relationships to disclose
August Garin
No relevant relationships to disclose
Stefan Hubert Boeck
Research Funding - Clovis
Volker Heinemann
Research Funding - University of Munich
Claudio Bassi
No relevant relationships to disclose
T. R. Jeffry Evans
Consultant or Advisory Role - Clovis
Research Funding - Clovis
Cynthia Voong
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Paramjit Kaur
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jeffrey D. Isaacson
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis